多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析

doi:10.3969/j.issn.1672-5069.2020.01.014

摘要/Abstract

摘要： 目的系统评价应用多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病(NAFLD)患者的疗效和安全性。方法全面检索知网(CNKI)、万方(WanFang Data)、维普(VIP)、EMbase、PubMed数据库,检索2018年8月前关于应用多烯磷脂酰胆碱联合二甲双胍治疗NAFLD患者的随机对照试验(RCT)研究,采用 RevMan 5.3 处理软件进行Meta 分析。结果纳入18项RCT研究包括1596例患者,其中试验组803例,对照组793例。给予试验组患者多烯磷脂酰胆碱联合二甲双胍治疗,给予对照组其它药物治疗。Meta分析结果显示,试验组在降低胰岛素抵抗指数(HOMA-IR)、空腹血糖(FPG)、AST水平、ALT水平、GGT水平、LDL-C水平、TC水平、TG水平和提高HDL-C水平、超声检查指标改善率和肝/脾CT值比值方面优于对照组,差异有统计学意义(P＜0.05);两组在降低空腹胰岛素(FINS)水平和不良反应发生率方面差异无统计学意义(P＞0.05)。结论应用多烯磷脂酰胆碱联合二甲双胍治疗NAFLD患者疗效较好,无明显不良反应。由于纳入研究的整体质量不高,仍需多中心和高质量的随机对照试验加以验证。

关键词: 非酒精性脂肪性肝病, 多烯磷脂酰胆碱, 二甲双胍, 治疗, Meta分析

Abstract: Objective This study aimed tosystematically evaluate the efficacy and safety of polyene phosphatidylcholine combined with metformin in the treatment of patients with non-alcoholic fatty liver disease (NAFLD). Methods We searched CNKI, WanFang Data, VIP, EMbase and PubMed for retrieving randomized controlled trials (RCT) on application of metformin and polyene phosphatidylcholine combination in treatment of patients with NAFLD before August 2018. The Meta analysis was carried out by using RevMan 5.3 software. Results Eighteen RCTs having 1596 patients with NAFLD were finally included, and 803 in observation received combination and 793 in the control received medicines without anyone of the two combined agents. The results showed that the efficacy in combination group was superior to that in the control as respect to the reduction of the homeostasis model assessment for insulin resistance (HOMA-IR) levels, fasting plasma glucose (FPG) levels, AST levels, ALT levels, GGT levels, LDL-C levels, TC levels, TG levels, increasing HDL-C levels, improving ultrasonic parameters, and liver/spleen CT value ratio (P＜0.05); there were no significantly differences in fasting insulin (FINS) levels and incidences of adverse effects between the two groups (P＞0.05). Conclusion The efficacy of polyene phosphatidylcholine combined with metformin in the treatment of patients with NAFLD is good without obvious adverse reactions. It is safe and reliable, and needs multi-centre verification as the low-level quality of all the studies included.

Key words: Non-alcoholic fatty liver diseases, Polyene phosphatidylcholine, Metformin, Therapy, Meta-analysis

魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.

Wei Zhongcao, Liu Na, Xing Xin, et al. Efficacy and safety ofpolyene phosphatidylcholine combined with metformin in the treatment of patients with non-alcoholic fatty liver disease: a Meta-analysis[J]. Journal of Practical Hepatology, 2020, 23(1): 46-49.

参考文献

[1] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease:Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md), 2016, 64(1): 73-84.
[2] Ipsen DH, Lykkesfeldt J, Tveden-nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci, 2018, 75(18):3313-3327.
[3] Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis.J Hepatol,2012, 57(1): 157-166.
[4] 冯凯瑜.复方牛胎肝提取物治疗非酒精性脂肪肝临床观察.实用肝脏病杂志,2014,17(3):311-312.
[5] Lassatlly G, Caiazzo R, Pattou F, et al. Perspectives on treatment for nonalcoholic steatohepatitis. Gastroenterology, 2016, 150(8): 1835-1848.
[6] 黄志鹏,苏智军,蒋建家.非酒精性脂肪性肝病的非基础治疗研究进展.实用肝脏病杂志,2013,16(2):181-183.
[7] EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J Hepatol, 2016, 64(6): 1388-1402.
[8] 非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2):177-186.
[9] 彭双凤. 多烯磷脂酰胆碱+二甲双胍治疗非乙醇性脂肪肝患者临床价值研究. 当代医学, 2017, 23(1): 96-97.
[10] 唐文, 赵长江, 李艺华. 多烯磷脂酰胆碱胶囊治疗NAFLD患者的效果观察. 中国卫生产业, 2011, 8(Z4): 49-50.
[11] 孙存序, 郑宪玲, 檀增桓, 等. 多烯磷脂酰胆碱联合二甲双胍治疗2型糖尿病合并非酒精性脂肪性肝病的临床观察. 临床荟萃, 2008, 17: 1272-1273.
[12] 丁燕萍, 王翼华, 王前, 等. 多烯磷脂酰胆碱联合二甲双胍治疗2型糖尿病合并非酒精性脂肪肝的疗效观察. 糖尿病新世界, 2015,12(8): 18-19.
[13] 黄静, 陈湘清, 郭东升, 等. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪肝的疗效. 中国老年学杂志, 2017, 37(24): 6127-6129.
[14] 何小荣, 洪涛, 余杰, 等. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪肝的疗效观察. 实用临床医学, 2010, 11(10): 14-16.
[15] 李世媛, 胡定海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪肝的疗效观察. 中国医药指南, 2017, 15(8): 93.
[16] 肖霞, 吴剑. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪肝的临床观察. 四川医学, 2012, 33(4): 674-675.
[17] 李桂芬, 袁静, 丁洁. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪肝的临床疗效分析. 医药论坛杂志, 2017, 38(2): 25-26.
[18] 张宇. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪肝疗效观察. 实用临床医药杂志, 2013, 17(11): 117-118.
[19] 张凤朝, 李洪霞, 吴璐. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病的疗效观察. 中国医药, 2008,12( z1): 14-15.
[20] 胡继新. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病的效果探讨. 当代医药论丛, 2017, 15(3): 111-112.
[21] 李治国. 多烯磷脂酰胆碱联合二甲双胍治疗糖尿病合并非酒精性脂肪性肝病的疗效观察. 内蒙古中医药, 2013, 32(31): 10-11.
[22] 刘真, 罗利华, 黄必武. 二甲双胍辅助治疗非酒精性脂肪肝的可行性及安全性. 中国当代医药, 2016, 23(17): 129-131,135.
[23] 黄英. 二甲双胍联合多烯磷脂酰胆碱对非酒精性脂肪肝的疗效观察. 中国伤残医学, 2015, 14(7): 17-19.
[24] 闫兰菊. 非酒精性脂肪肝应用多烯磷脂酰胆碱辅以二甲双胍的疗效. 医药论坛杂志, 2014, 35(9): 142-143.
[25] 康成慧. 联用多烯磷脂酰胆碱和二甲双胍治疗非酒精性脂肪性肝病的效果评析. 当代医药论丛, 2017, 15(13): 114-115.
[26] 乔永刚, 赵立平, 张妮. 易善复联合二甲双胍治疗肥胖相关非酒精性脂肪肝临床观察. 内蒙古中医药, 2014, 33(6): 13.
[27] Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) : pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev, 2017, 49(2): 197-211.
[28] Lebeaupin C, Vall ED, Hazari Y, et al. Endoplasmic reticulum stress signaling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol, 2018,69(4):927-947.
[29] Rotman Y, Sanyal A. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut, 2017, 66(1): 180-190.
[30] Iogna Prat L, Tsochatzis E. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones (Athens), 2018, 17(2): 219-229.
[31] Foretz M, Guigas B, Bertrand L, et al. Metformin: from mechanisms of action to therapies. Cell Metab, 2014, 20(6): 953-966.
[32] Okiyama W, Tanka N, Nakajima T, et al. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress. J Hepatol, 2009, 50(6): 1236-1246.
[33] 周志菁,黄永东.多烯磷脂酰胆碱治疗中重度非酒精性脂肪性肝病患者疗效初步研究.实用肝脏病杂志,2018,21(5):733-736.